{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:55:22Z","timestamp":1781636122718,"version":"3.54.5"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Health Sciences"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To evaluate the correlation between prostate morphological measurements and changes in ejaculatory function during short-term tamsulosin therapy in men with benign prostatic hyperplasia (BPH).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective study included 214 sexually active men with moderate-to-severe lower urinary tract symptoms (LUTS) who received tamsulosin 0.4\u00a0mg\/day for eight weeks. Patients with prior treatment for BPH or pre-existing sexual dysfunction were excluded. Symptom severity and ejaculatory function were evaluated using the International Prostate Symptom Score (IPSS) and the Male Sexual Health Questionnaire\u2013Ejaculatory Dysfunction Short Form (MSHQ-EjD-SF). Prostate morphological measurements, including overall dimensions and intravesical prostatic protrusion (IPP), were obtained by transabdominal ultrasonography. Correlations between changes in MSHQ-EjD scores (\u0394MSHQ-EjD) and clinical or anatomical variables were assessed using Spearman\u2019s rank coefficients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After eight weeks of treatment, the median IPSS significantly decreased from 18 to 14 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and Qmax increased from 9.2 to 14.0 mL\/s (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The median MSHQ-EjD-SF score declined from 11 to 7 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), while higher ejaculatory bother scores were observed after treatment. \u0394MSHQ-EjD was negatively correlated with IPP (\u03c1 = \u22120.386), prostate length (\u03c1 = \u22120.250), and age (\u03c1 = \u22120.334) (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Patients with IPP\u2009&gt;\u200910\u00a0mm showed a less pronounced decline in ejaculatory function compared with lower IPP grades (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tamsulosin improved urinary symptoms but was associated with a decline in ejaculatory function. Prostate morphological characteristics, particularly IPP\u2009&gt;\u200910\u00a0mm and longer prostate length, were associated with a less pronounced decline in ejaculatory function. Although these correlations were modest, the findings may help contextualize the relationship between prostate anatomy and tamsulosin-related ejaculatory changes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00345-026-06266-8","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:23:37Z","timestamp":1771349017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Correlation between intravesical prostatic protrusion and ejaculatory dysfunction after tamsulosin treatment in men with BPH"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1634-4516","authenticated-orcid":false,"given":"Cem Tu\u011frul","family":"Gezmi\u015f","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2115-698X","authenticated-orcid":false,"given":"Nusret Can","family":"\u00c7ilesiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9010-773X","authenticated-orcid":false,"given":"Veli Huzeyfe","family":"Kartal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1444-9411","authenticated-orcid":false,"given":"Mahmut Kemal","family":"Altan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5337-5226","authenticated-orcid":false,"given":"Basri","family":"\u00c7ak\u0131ro\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0395-1154","authenticated-orcid":false,"given":"Mustafa Bahad\u0131r Can","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"3","key":"6266_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ajur.2017.06.004","volume":"4","author":"KB Lim","year":"2017","unstructured":"Lim KB (2017) Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol 4(3):148\u2013151. https:\/\/doi.org\/10.1016\/j.ajur.2017.06.004","journal-title":"Asian J Urol"},{"issue":"2","key":"6266_CR2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.eururo.2023.04.008","volume":"84","author":"S Gravas","year":"2023","unstructured":"Gravas S, Gacci M, Gratzke C, Herrmann TRW, Karavitakis M, Kyriazis I, Malde S, Mamoulakis C, Rieken M, Sakalis VI, Schouten N, Speakman MJ, Tikkinen KAO, Cornu JN (2023) Summary paper on the 2023 European association of urology guidelines on the management of non-neurogenic male lower urinary tract symptoms. Eur Urol 84(2):207\u2013222. https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008","journal-title":"Eur Urol"},{"key":"6266_CR3","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000003698","author":"JS Sandhu","year":"2023","unstructured":"Sandhu JS, Bixler BR, Dahm P et al (2023) Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia (BPH): AUA guideline amendment 2023. J Urol. https:\/\/doi.org\/10.1097\/JU.0000000000003698","journal-title":"J Urol"},{"issue":"9","key":"6266_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1001\/jama.2025.7045","volume":"334","author":"JT Wei","year":"2025","unstructured":"Wei JT, Dauw CA, Brodsky CN (2025) Lower urinary tract symptoms in men: a review. JAMA 334(9):809\u2013821. https:\/\/doi.org\/10.1001\/jama.2025.7045","journal-title":"JAMA"},{"issue":"1","key":"6266_CR5","doi-asserted-by":"publisher","first-page":"11116","DOI":"10.1038\/s41598-024-61977-5","volume":"14","author":"BT Yoosuf","year":"2024","unstructured":"Yoosuf BT, Panda AK, Kt MF, Bharti SK, Devana SK, Bansal D (2024) Comparative efficacy and safety of alpha-blockers as monotherapy for benign prostatic hyperplasia: a systematic review and network meta-analysis. Sci Rep 14(1):11116. https:\/\/doi.org\/10.1038\/s41598-024-61977-5","journal-title":"Sci Rep"},{"issue":"Suppl 2","key":"6266_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/j.1464-410X.2006.06104.x","volume":"97","author":"F Giuliano","year":"2006","unstructured":"Giuliano F (2006) Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 97(Suppl 2):34\u201338 discussion 44\u201345. https:\/\/doi.org\/10.1111\/j.1464-410X.2006.06104.x","journal-title":"BJU Int"},{"issue":"3","key":"6266_CR7","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","volume":"59","author":"CR Chapple","year":"2011","unstructured":"Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fern\u00e1ndez Fern\u00e1ndez E, European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59(3):342\u2013352. https:\/\/doi.org\/10.1016\/j.eururo.2010.10.046","journal-title":"Eur Urol"},{"key":"6266_CR8","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.urology.2020.01.027","volume":"139","author":"C Pavone","year":"2020","unstructured":"Pavone C, Abrate A, Li Muli P, Guzzardo C, Guarneri AG, Dioguardi S, Sanfilippo C, Vella M, Serretta V, Simonato A (2020) Can we clinically distinguish anejaculation from retrograde ejaculation in patients on \u03b11A-Blockers therapy for lower urinary tract symptoms? Urology 139:129\u2013133. https:\/\/doi.org\/10.1016\/j.urology.2020.01.027","journal-title":"Urology"},{"issue":"6","key":"6266_CR9","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00345-002-0246-7","volume":"19","author":"C Chapple","year":"2002","unstructured":"Chapple C, Andersson KE (2002) Tamsulosin: an overview. World J Urol 19(6):397\u2013404. https:\/\/doi.org\/10.1007\/s00345-002-0246-7","journal-title":"World J Urol"},{"issue":"6","key":"6266_CR10","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S0090-4295(98)00127-7","volume":"51","author":"H Lepor","year":"1998","unstructured":"Lepor H, Tamsulosin Investigator Group (1998) Long-term evaluation of Tamsulosin in benign prostatic hyperplasia: placebo-controlled, double-blind extension of phase III trial. Urology 51(6):901\u2013906. https:\/\/doi.org\/10.1016\/S0090-4295(98)00127-7","journal-title":"Urology"},{"issue":"6","key":"6266_CR11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1111\/jsm.12525","volume":"11","author":"M Gacci","year":"2014","unstructured":"Gacci M, Ficarra V, Sebastianelli A, Corona G, Serni S, Shariat SF, Maggi M, Zattoni F, Carini M, Novara G (2014) Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 11(6):1554\u20131566. https:\/\/doi.org\/10.1111\/jsm.12525","journal-title":"J Sex Med"},{"issue":"6","key":"6266_CR12","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/aja.2011.25","volume":"13","author":"SH Song","year":"2011","unstructured":"Song SH, Son H, Kim KT, Kim SW, Moon DG, Moon KH, Park K, Park JK, Lee SW, Hyun JS, Park NC (2011) Effect of Tamsulosin on ejaculatory function in BPH\/LUTS. Asian J Androl 13(6):846\u2013850. https:\/\/doi.org\/10.1038\/aja.2011.25","journal-title":"Asian J Androl"},{"issue":"2","key":"6266_CR13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/j.2047-2927.2013.00176.x","volume":"2","author":"M Kendirci","year":"2014","unstructured":"Kendirci M, Asci R, Yaman O, Cayan S, Orhan I, Usta MF, Ekmekcioglu O, Kadioglu A (2014) Prevalence of male pelvic dysfunction: results from the Turkish society of andrology male sexual health study group. Andrology 2(2):219\u2013224. https:\/\/doi.org\/10.1111\/j.2047-2927.2013.00176.x","journal-title":"Andrology"},{"issue":"1","key":"6266_CR14","first-page":"45","volume":"33","author":"TDSGS Turunc","year":"2007","unstructured":"Turunc TDSGS, Deveci S, G\u00fcvel S, Pe\u015fkircio\u011flu L (2007) The assessment of Turkish validation with 5 question version of international index of erectile function (IIEF-5). Turk J Urol 33(1):45\u201349","journal-title":"Turk J Urol"},{"issue":"5","key":"6266_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.urology.2007.02.036","volume":"69","author":"RC Rosen","year":"2007","unstructured":"Rosen RC, Catania JA, Althof SE, Pollack LM, O\u2019Leary M, Seftel AD, Coon DW (2007) Development and validation of four-item version of male sexual health questionnaire to assess ejaculatory dysfunction. Urology 69(5):805\u2013809. https:\/\/doi.org\/10.1016\/j.urology.2007.02.036","journal-title":"Urology"},{"key":"6266_CR16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/978-1-4684-2892-6_7","volume-title":"Physiology and genetics of reproduction: part B","author":"H Marberger","year":"1974","unstructured":"Marberger H (1974) The mechanisms of ejaculation. In: Coutinho EM, Fuchs F (eds) Physiology and genetics of reproduction: part B. Springer US, Boston, MA, pp 99\u2013110"},{"issue":"1","key":"6266_CR17","first-page":"19","volume":"53","author":"C Terrone","year":"2001","unstructured":"Terrone C, Castelli E, Aveta P, Cugudda A, Rocca Rossetti S (2001) Iatrogenic ejaculation disorders and their prevention. Minerva Urol Nefrol 53(1):19\u201328","journal-title":"Minerva Urol Nefrol"},{"key":"6266_CR18","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/S0022-5347(17)61195-9","volume":"107","author":"JE McNeal","year":"1972","unstructured":"McNeal JE (1972) The prostate and prostatic urethra: a morphologic synthesis. J Urol 107:1008\u20131016","journal-title":"J Urol"},{"key":"6266_CR19","first-page":"305","volume":"9","author":"J Hermabessiere","year":"1999","unstructured":"Hermabessiere J, Guy L, Boiteux JP (1999) Human ejaculation: physiology, surgical conservation of ejaculation. Prog Urol 9:305\u2013309","journal-title":"Prog Urol"},{"key":"6266_CR20","doi-asserted-by":"publisher","unstructured":"Pradere B, Uleri A, Brugui\u00e8re E, Misrai V (2025) Exploration of the ejaculatory anatomy concept: the EJAC sLtudy. Eur Urol. Aug 25:S0302-2838(25)00451-8. https:\/\/doi.org\/10.1016\/j.eururo.2025.08.001","DOI":"10.1016\/j.eururo.2025.08.001"},{"issue":"3","key":"6266_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41391-023-00686-y","volume":"26","author":"M Sibona","year":"2023","unstructured":"Sibona M, Destefanis P, Vercelli E, Secco S, Gontero P, Cindolo L (2023) Ejaculation physiology and dysfunction after BPH surgery: the role of the new mists. Prostate Cancer Prostatic Dis 26(3):475\u2013482. https:\/\/doi.org\/10.1038\/s41391-023-00686-y","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"6266_CR22","doi-asserted-by":"publisher","unstructured":"Kim M, Song SH, Ku JH, Kim HJ, Paick JS Pilot study of the clinical efficacy of ejaculatory Hood sparing technique for ejaculation preservation in holmium laser enucleation of the prostate. Int J Impot Res 2015 Jan-Feb ;27(1):20\u201324. https:\/\/doi.org\/10.1038\/ijir.2014.22","DOI":"10.1038\/ijir.2014.22"},{"issue":"1","key":"6266_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.5114\/wiitm.2018.79536","volume":"14","author":"J Liao","year":"2019","unstructured":"Liao J, Zhang X, Chen M, Li D, Tan X, Gu J, Hu S, Chen X (2019) Transurethral resection of the prostate with preservation of the bladder neck decreases postoperative retrograde ejaculation. Wideochir Inne Tech Maloinwazyjne 14(1):96\u2013101. https:\/\/doi.org\/10.5114\/wiitm.2018.79536","journal-title":"Wideochir Inne Tech Maloinwazyjne"},{"issue":"11","key":"6266_CR24","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1007\/s00345-021-03752-z","volume":"39","author":"M Elshazly","year":"2021","unstructured":"Elshazly M, Sultan S, Shaban M, Zanaty F (2021) Evaluation of a novel technique of bladder neck and supramontanal sparing ejaculatory preserving transurethral prostatectomy. World J Urol 39(11):4215\u20134219. https:\/\/doi.org\/10.1007\/s00345-021-03752-z","journal-title":"World J Urol"},{"issue":"3","key":"6266_CR25","doi-asserted-by":"publisher","first-page":"292","DOI":"10.5173\/ceju.2022.0004","volume":"75","author":"T Manasa","year":"2022","unstructured":"Manasa T, Reddy N, Puvvada S, Mylarappa P (2022) Evaluating outcomes of combined bladder neck and supramontanal sparing ejaculatory preserving transurethral resection of the prostate: results from a prospective, randomised study. Cent Eur J Urol 75(3):292\u2013298. https:\/\/doi.org\/10.5173\/ceju.2022.0004","journal-title":"Cent Eur J Urol"},{"issue":"4","key":"6266_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000019996","volume":"36","author":"K H\u00f6fner","year":"1999","unstructured":"H\u00f6fner K, Claes H, De Reijke TM, Folkestad B, Speakman MJ (1999) Tamsulosin 0.4\u00a0mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36(4):335\u2013341. https:\/\/doi.org\/10.1159\/000019996","journal-title":"Eur Urol"},{"issue":"6","key":"6266_CR27","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1111\/andr.12095","volume":"3","author":"P Capogrosso","year":"2015","unstructured":"Capogrosso P, Serino A, Ventimiglia E, Boeri L, Deh\u00f2 F, Damiano R, Briganti A, Montorsi F, Salonia A (2015) Effects of silodosin on sexual function: a realistic picture from everyday clinical practice. Andrology 3(6):1076\u20131081. https:\/\/doi.org\/10.1111\/andr.12095","journal-title":"Andrology"},{"key":"6266_CR28","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1159\/000480808","volume":"32","author":"CR Chapple","year":"1997","unstructured":"Chapple CR, Baert L, Thind P et al (1997) Tamsulosin 0.4\u00a0mg once daily: tolerability in older and younger patients with lower urinary tract symptoms suggestive of benign prostatic obstruction (symptomatic BPH). The European Tamsulosin study group. Eur Urol 32:462\u2013470","journal-title":"Eur Urol"},{"issue":"4","key":"6266_CR29","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/sj.ijir.3901017","volume":"15","author":"DJ Carbone Jr","year":"2003","unstructured":"Carbone DJ Jr, Hodges S (2003) Medical therapy for benign prostatic hyperplasia: sexual dysfunction and impact on quality of life. Int J Impot Res 15(4):299\u2013306. https:\/\/doi.org\/10.1038\/sj.ijir.3901017","journal-title":"Int J Impot Res"},{"issue":"9\u201310","key":"6266_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.2298\/SARH1410572S","volume":"142","author":"N Stojanovi\u0107","year":"2014","unstructured":"Stojanovi\u0107 N, Bogdanovi\u0107 D (2014) Improvement of sexual function in men with benign prostatic hyperplasia by pharmacologic therapy. Srp Arh Celok Lek 142(9\u201310):572\u2013578. https:\/\/doi.org\/10.2298\/SARH1410572S","journal-title":"Srp Arh Celok Lek"},{"issue":"7","key":"6266_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1111\/iju.12412","volume":"21","author":"JJ Kim","year":"2014","unstructured":"Kim JJ, Han DH, Sung HH, Choo SH, Lee SW (2014) Efficacy and tolerability of Tamsulosin 0.4\u00a0mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to Tamsulosin 0.2\u00a0mg: a randomized placebo-controlled trial. Int J Urol 21(7):677\u2013682. https:\/\/doi.org\/10.1111\/iju.12412","journal-title":"Int J Urol"},{"issue":"2","key":"6266_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eursup.2004.10.010","volume":"4","author":"CR Chapple","year":"2005","unstructured":"Chapple CR, Al-Shukri SH, Gattegno B, Holmes S, Mart\u00ednez-Sagarra JM, Scarpa RM, van der Putten-Slob I (2005) Tamsulosin oral controlled absorption system (OCAS) in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS\/BPH): efficacy and tolerability in a placebo- and active-comparator-controlled phase 3a study. Eur Urol Suppl 4(2):33\u201344. https:\/\/doi.org\/10.1016\/j.eursup.2004.10.010","journal-title":"Eur Urol Suppl"},{"issue":"5","key":"6266_CR33","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1016\/S0022-5347(01)62386-3","volume":"160","author":"P Narayan","year":"1998","unstructured":"Narayan P, Tewari A, United States 93\u2009\u2013\u200901 Study Group (1998) A second phase III multicenter placebo-controlled study of two dosages of modified release Tamsulosin in patients with symptoms of benign prostatic hyperplasia. J Urol 160(5):1701\u20131706","journal-title":"J Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-026-06266-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-026-06266-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:23:16Z","timestamp":1781634196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-026-06266-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6266"],"URL":"https:\/\/doi.org\/10.1007\/s00345-026-06266-8","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"10 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the principles of the Declaration of Helsinki and was approved by the Ethics Board of Taksim Training and Research Hospital (March 5, 2025; No. 27).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}}],"article-number":"180"}}